FDA Brief

Warning letters Drugs

FDA warning letter to

Cureganics

High riskIssued Mar 28, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

Cureganics sold CBD products with website claims they prevent or treat COVID-19, making them unapproved and misbranded drugs.

What happened

FDA reviewed Cureganics' website on February 15, 2022, and found it offered CBD products for sale with wording that made them intended to prevent, treat, diagnose, or cure COVID-19. The letter cites a webpage quoting a Forbes report that cannabis compounds can prevent infection by the virus that causes COVID-19. FDA said these are unapproved new drugs and misbranded drugs.

What FDA found

  1. FDA says the CBD products are unapproved new drugs because they are promoted for COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. FDA says the products are misbranded drugs, meaning their labeling or promotion is misleading under the FD&C Act.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Selling or shipping these products in interstate commerce is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that its products can prevent, treat, or cure COVID-19 without reliable scientific evidence, including well-controlled human studies.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. Deceptive COVID-19 treatment, cure, prevention, or mitigation claims can bring civil penalties of up to $46,517 per violation.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks Cureganics to take immediate action to stop selling any unapproved products for COVID-19 and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and how it will prevent recurrence. The FTC separately asks for a certification within 48 hours that the unsubstantiated claims have ceased.

Who should pay attention

  • online CBD and supplement sellers
  • companies making COVID-19 health claims
  • retailers and platforms hosting CBD product listings

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk